Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q8N135

UPID:
LGI4_HUMAN

ALTERNATIVE NAMES:
LGI1-like protein 3; Leucine-rich glioma-inactivated protein 4

ALTERNATIVE UPACC:
Q8N135; B2RN53; B9EGS7; Q5M8T1

BACKGROUND:
Leucine-rich repeat LGI family member 4, identified by its alternative names LGI1-like protein 3 and Leucine-rich glioma-inactivated protein 4, is a key component in the signaling pathways of Schwann cells. These pathways are essential for axon segregation and the formation of myelin, highlighting the protein's significance in neural development and function.

THERAPEUTIC SIGNIFICANCE:
This protein's malfunction is associated with Arthrogryposis multiplex congenita 1, characterized by severe neurogenic defects and compromised myelin around peripheral nerves. Exploring the functions of Leucine-rich repeat LGI family member 4 offers a promising avenue for developing treatments for this and potentially other neurogenic disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.